Tags : Live Biotherapeutics

MSD Signs a Research and Option to License Agreement with

Shots: 4D to receive up front in cash for each indication, ~$347.5M as option exercise fee, development & commercialization milestones with royalties on sales of licensed product derived from the collaboration. 4D has rights to cause MSD to purchase 4D shares for $5M during the first 12 mos. of the collaboration The agreement will combine […]Read More

NIH Launches LUCA Biologics to Develop Live Biotherapeutics for Women’s

Shots: NIH has launched LUCA Biologics in Cambridge, Massachusetts focusing on women’s health by initially targeting UTI with its anticipated clinical study and initiation of recruitment of patients in H2’19 LUCA initiates with a strain bank and gene catalog developed over 15yrs. from Gates Foundation and NIH-funded research and has built a metagenomic and metatranscriptomic […]Read More